Drugs / CTN SR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02547428 | Aug 2015 → Jun 2016 | attention deficit-hyperactivity disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTN SR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02547428 ↗ |
| Route | Oral | “CTN SR tablets, daily, Orally.” NCT02547428 ↗ |